Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein.

[1]  H. Ebihara,et al.  An Improved Reverse Genetics System to Overcome Cell-Type-Dependent Ebola Virus Genome Plasticity. , 2015, The Journal of infectious diseases.

[2]  Update: Ebola Virus Disease Epidemic — West Africa, January 2015 , 2015, MMWR. Morbidity and mortality weekly report.

[3]  S. Baize.  Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus. , 2015, Current opinion in virology.

[4]  John G Kenny,et al.  Elucidating variations in the nucleotide sequence of Ebola virus associated with increasing pathogenicity , 2014, Genome Biology.

[5]  J. Phillips.  Ebola Virus Disease Epidemic , 2014, Workplace health & safety.

[6]  Stephan Günther,et al.  Emergence of Zaire Ebola virus disease in Guinea. , 2014, The New England journal of medicine.

[7]  Tanja Stadler,et al.  Insights into the Early Epidemic Spread of Ebola in Sierra Leone Provided by Viral Sequence Data , 2014, PLoS currents.

[8]  Rachel S. G. Sealfon,et al.  Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak , 2014, Science.

[9]  Thomas Hoenen,et al.  Reverse genetics systems as tools for the development of novel therapies against filoviruses , 2014, Expert review of anti-infective therapy.

[10]  Derek Gatherer,et al.  The 2014 Ebola virus disease outbreak in West Africa. , 2014, The Journal of general virology.

[11]  Ilana J. Schafer,et al.  Ebola Viral Disease Outbreak — West Africa, 2014 , 2014, MMWR. Morbidity and mortality weekly report.

[12]  S. Nichol,et al.  High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. , 2014, Antiviral research.

[13]  S. Nichol,et al.  Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. , 2014, Antiviral research.

[14]  H. Feldmann,et al.  Possible leap ahead in filovirus therapeutics , 2014, Cell Research.

[15]  A. McElroy,et al.  Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate. , 2013, Virology.

[16]  A. Takada,et al.  A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. , 2013, Antiviral research.

[17]  Gordian Schudt,et al.  Live-cell imaging of Marburg virus-infected cells uncovers actin-dependent transport of nucleocapsids over long distances , 2013, Proceedings of the National Academy of Sciences.

[18]  P. Rollin,et al.  Genomic analysis of filoviruses associated with four viral hemorrhagic fever outbreaks in Uganda and the Democratic Republic of the Congo in 2012. , 2013, Virology.

[19]  Heinz Feldmann,et al.  Filoviridae: Marburg and ebola viruses , 2013 .

[20]  Thomas Hoenen,et al.  Inclusion Bodies Are a Site of Ebolavirus Replication , 2012, Journal of Virology.

[21]  H. Ebihara,et al.  The Ebola Virus Glycoprotein Contributes to but Is Not Sufficient for Virulence In Vivo , 2012, PLoS pathogens.

[22]  S. Bavari,et al.  Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. , 2012, Antiviral research.

[23]  V. Krähling,et al.  Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread. , 2011, The Journal of infectious diseases.

[24]  V. Volchkov,et al.  Role of VP30 phosphorylation in the Ebola virus replication cycle. , 2011, The Journal of infectious diseases.

[25]  J. Kuhn,et al.  Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. , 2011, Antiviral research.

[26]  J. Gonzalez,et al.  Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  H. Park,et al.  High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice , 2011, PloS one.

[28]  G. Ruthel,et al.  Development of High-Content Imaging Assays for Lethal Viral Pathogens , 2010, Journal of biomolecular screening.

[29]  T. Takimoto,et al.  Trafficking of Sendai Virus Nucleocapsids Is Mediated by Intracellular Vesicles , 2010, PloS one.

[30]  S. Nichol,et al.  Ebola and marburg hemorrhagic fever. , 2010, Clinics in laboratory medicine.

[31]  S. Zaki,et al.  Inhibition of IRF-3 Activation by VP35 Is Critical for the High Level of Virulence of Ebola Virus , 2008, Journal of Virology.

[32]  G. Neumann,et al.  In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein. , 2007, The Journal of infectious diseases.

[33]  W. P. Duprex,et al.  Development of a Challenge-Protective Vaccine Concept by Modification of the Viral RNA-Dependent RNA Polymerase of Canine Distemper Virus , 2007, Journal of Virology.

[34]  S. Nichol,et al.  Reverse Genetic Generation of Recombinant Zaire Ebola Viruses Containing Disrupted IRF-3 Inhibitory Domains Results in Attenuated Virus Growth In Vitro and Higher Levels of IRF-3 Activation without Inhibiting Viral Transcription or Replication , 2006, Journal of Virology.

[35]  B. Berkhout,et al.  Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle , 2006, Antimicrobial Agents and Chemotherapy.

[36]  V. Volchkov,et al.  Rescue of Recombinant Marburg Virus from cDNA Is Dependent on Nucleocapsid Protein VP30 , 2006, Journal of Virology.

[37]  G. Neumann,et al.  The role of reverse genetics systems in studying viral hemorrhagic fevers , 2005, Thrombosis and Haemostasis.

[38]  C. Goldsmith,et al.  Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. , 2005, Virology.

[39]  H. Artsob,et al.  The role of reverse genetics systems in determining filovirus pathogenicity. , 2005, Archives of virology. Supplementum.

[40]  Natale Scaramozzino,et al.  Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. , 2003, Antiviral research.

[41]  W. P. Duprex,et al.  Modulating the Function of the Measles Virus RNA-Dependent RNA Polymerase by Insertion of Green Fluorescent Protein into the Open Reading Frame , 2002, Journal of Virology.

[42]  D. Smee,et al.  Identification of active antiviral compounds against a New York isolate of West Nile virus. , 2002, Antiviral research.

[43]  Shinji Watanabe,et al.  Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture , 2002, Journal of Virology.

[44]  V. Volchkov,et al.  Recovery of Infectious Ebola Virus from Complementary DNA: RNA Editing of the GP Gene and Viral Cytotoxicity , 2001, Science.

[45]  G. Coulton.  Live cell imaging. , 1998, The Histochemical journal.

[46]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[47]  D. Smee,et al.  Novel pyrazolo[3,4-d]pyrimidine nucleoside analog with broad-spectrum antiviral activity , 1987, Antimicrobial Agents and Chemotherapy.

[48]  Ebola haemorrhagic fever in Zaire, 1976. , 1978, Bulletin of the World Health Organization.

[49]  K. Johnson,et al.  ISOLATION AND PARTIAL CHARACTERISATION OF A NEW VIRUS CAUSING ACUTE HÆMORRHAGIC FEVER IN ZAIRE , 1977, The Lancet.